Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries

Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries

Background: The experience of Kymriah® and Yescarta® provides real-world examples of how health-care systems approach and manage the reimbursement of one-off, high-cost, cell, and gene therapies, and the decision uncertainty and affordability challenges they present. Objective: To provide an overvie...

Full description

Bibliographic Details
Main Authors: Jesper Jørgensen, Eve Hanna, Panos Kefalas
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Journal of Market Access & Health Policy
Subjects:
health technology assessment (hta)
reimbursement
market access
gene therapy
chimeric antigen receptor (car) t-cell therapy
oncology
haematology
Online Access:http://dx.doi.org/10.1080/20016689.2020.1715536

Internet

http://dx.doi.org/10.1080/20016689.2020.1715536

Similar Items